1. Home
  2. ELOX vs TELA Comparison

ELOX vs TELA Comparison

Compare ELOX & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ELOX

Eloxx Pharmaceuticals Inc. Common Stock

N/A

Current Price

$11.66

Market Cap

43.8M

Sector

N/A

ML Signal

N/A

Logo TELA Bio Inc.

TELA

TELA Bio Inc.

N/A

Current Price

$0.81

Market Cap

41.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ELOX
TELA
Founded
N/A
2012
Country
United States
United States
Employees
7
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.8M
41.3M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
ELOX
TELA
Price
$11.66
$0.81
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$2.00
AVG Volume (30 Days)
48.2K
85.2K
Earning Date
N/A
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.59
EPS
N/A
N/A
Revenue
N/A
$80,275,000.00
Revenue This Year
N/A
$10.23
Revenue Next Year
N/A
$14.26
P/E Ratio
N/A
N/A
Revenue Growth
N/A
15.84
52 Week Low
$10.00
$0.50
52 Week High
$15.00
$2.19

Technical Indicators

Market Signals
Indicator
ELOX
TELA
Relative Strength Index (RSI) 38.06 51.00
Support Level N/A $0.78
Resistance Level $15.00 $0.94
Average True Range (ATR) 2.29 0.10
MACD -0.09 0.01
Stochastic Oscillator 27.50 49.29

Price Performance

Historical Comparison
ELOX
TELA

About ELOX Eloxx Pharmaceuticals Inc. Common Stock

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.

About TELA TELA Bio Inc.

TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

Share on Social Networks: